{"id":7790,"date":"2019-04-24T12:28:18","date_gmt":"2019-04-24T11:28:18","guid":{"rendered":"http:\/\/161.116.26.48\/?page_id=7790"},"modified":"2022-02-22T12:51:27","modified_gmt":"2022-02-22T10:51:27","slug":"pharmacological-targets-in-inflammation-and-metabolic-disease","status":"publish","type":"page","link":"https:\/\/www.fbg.ub.edu\/en\/researchers\/research-groups-of-the-ub\/pharmacological-targets-in-inflammation-and-metabolic-disease\/","title":{"rendered":"Pharmacological targets in inflammation and metabolic disease"},"content":{"rendered":"<p>With more than 10 years\u2019 experience in the field of <strong>pharmacology,<\/strong> <strong>inflammation<\/strong> and <strong>metabolic diseases<\/strong>, the Laboratory of Pharmacological Targets in Inflammation and Metabolic Diseases focuses its research in the <strong>molecular mechanisms <\/strong>that connect inflammation, insulin resistance and\u00a0 other metabolic disorders responsible for human diseases as diabetes, cardiomyopathies, or liver diseases.<\/p>\n<h3>WHAT WE DO<\/h3>\n<h3>Services<\/h3>\n<p>The group possesses long expertise in developing in vivo experimental models and biochemical and molecular techniques in order to better understand the mechanisms related to inflammation and metabolic processes related to pathologic situations as diabetes, cardiomyopathies and liver diseases (NAFLD and NASH):<\/p>\n<p><strong>Experimental in vivo models<\/strong><strong>: <\/strong><\/p>\n<p>The team works regularly with double KO mouse models PPAR\u03b2\/\u03c3<sup>-\/ &#8211;<\/sup>, ATF3<sup>-\/-, <\/sup>GADD45<sup>-\/-<\/sup>\u00a0* in different disease in mouse models:<\/p>\n<ul>\n<li>Obesity<\/li>\n<li>Type 2 Diabetes Mellitus: Fat Diet Insulin Resistance model<\/li>\n<li>Metabolic liver disesases (NAFLD and NASH): liver steatosis from fat<\/li>\n<li>Cardiomyopaty (in collaboration with St. Pau i la Santa Creu Hospital)<\/li>\n<\/ul>\n<p>They also offer other <strong>in vivo <\/strong>and<strong> in vitro methodological services<\/strong>:<\/p>\n<ul>\n<li>Experimental animals manipulation and food and drugs administration<\/li>\n<li>Human samples manipulation: blood and adipose tissue biopsies<\/li>\n<li>Cell cultures: adipocytes, hepatocytes and skeletal muscular cells (myotubes):\n<ul>\n<li>Human liver cell lines: HepG2 i Huh7<\/li>\n<li>Human (and mouse) adipocite cell line 3T3-L1<\/li>\n<li>Cardiomyocite cell line- mouse myoblasts<\/li>\n<\/ul>\n<\/li>\n<li>Triglycerides (TG) accumulation and quantification: Hematoxylin-eosin and ORO (Oil Red O) staining techniques<\/li>\n<li>Glucose, cholesterol and triglycerides levels measurement in plasma<\/li>\n<li>Lipid accumulation in hepatocytes (TG, VLDL, HDL,\u2026): Oil Red O staining<\/li>\n<li>Complex lipids (diacylglycerols and ceramides) analysis- dyslipidemia studies<\/li>\n<li>Glucose Tolerance Test (GTT)<\/li>\n<li>Glucose uptake: 2-Deoxy-D-(1,2-[3H]N)glucose uptake<\/li>\n<li>Insulin Tolerance Tests (ITT)<\/li>\n<li>ROS estudies<\/li>\n<li>Nuclear Transcription Factor studies by using EMSA technique (from mouse)<\/li>\n<li>Gene (real time PCR) and protein (Western Blot) expression assays<\/li>\n<li>ELISA<\/li>\n<\/ul>\n<h3>FOR WHOM WE WORK<\/h3>\n<h3>Industrial sectors<\/h3>\n<ul>\n<li>Health and life sciences<\/li>\n<li>Cattle and Veterinary<\/li>\n<\/ul>\n<h3>Partners<\/h3>\n<ul>\n<li>Ciberdem<\/li>\n<li>Almirall<\/li>\n<li>F2I Val<\/li>\n<li>CaixaImpulse<\/li>\n<li>La Marat\u00f3 TV3<\/li>\n<\/ul>\n<h3>RESEARCH<\/h3>\n<h3>Research projects<\/h3>\n<ul>\n<li><strong>New HRI activators for the treatment of type 2 diabetes mellitus. 2018-2019. <\/strong>CaixaImpulse. PI: Manuel Vazquez Carrera, PhD.<\/li>\n<li><strong>Inflammation, resistance to insulin and diabetic cardiomyopathy: evaluation of PARbeta\/delta and oleic. 2016-2018. <\/strong>Ref #. SAF2015-64146-R. Ministerio de Economia y Competitividad . PI: Manuel Vazquez Carrera, PhD.<\/li>\n<li><strong>Diabetic cardiomyopathy: searching for a therapeutic target. 2016-2018.<\/strong> Ref#20154230. Duration, from: 2016 until: 2018. Fundaci\u00f3 La Marat\u00f3 de TV3. PI: Manuel Vazquez Carrera, PhD.<\/li>\n<li><strong>Hyperinsulinemia and inflammation as negative regulators of sensitivity to insulin: effect of activators of PPARb\/d and oleic acid in in vitro and in vivo models of insulin resistance. 2013-2015. <\/strong>Ref#: SAF2012-30708. Ministerio de Economia y Competitividad. PI: Manuel Vazquez Carrera, PhD.<\/li>\n<\/ul>\n<h3>RESULTS<\/h3>\n<h3>Transfer activities<\/h3>\n<p><strong>PATENTS<\/strong><\/p>\n<p><strong>\u201cHRI Activators useful for the treatment of metabolic diseases\u201d.<\/strong> 2016. WO2018010856. University of Barcelona . Inventors:\u00a0 Zarei, M; V\u00e1zquez-Carrera, M; V\u00e1zquez-Cruz, S; Leiva Mart\u00ednez, R; Pujol Bech, E.<\/p>\n<p><strong>\u201cAnalogs of adamantylureas as soluble epoxide hydrolase inhibitors\u201d. <\/strong>2015. WO2017017048. University of Barcelona. Inventors: V\u00e1zquez Cruz, S; Valverde Murillo, E.; Leiva Mart\u00ednez, R; V\u00e1zquez Carrera, M.; Codony Gispert, S.<\/p>\n<h3>Publications<\/h3>\n<ul>\n<li>Aguilar-Recarte D, et al. <strong>GDF15 mediates the metabolic effects of PPAR<\/strong><strong>\u03b2<\/strong><strong>\/<\/strong><strong>\u03b4<\/strong><strong> by activating AMPK. <\/strong>Cell Rep. 2021 Aug;36(6):109501.<\/li>\n<li>Palomer X, et al. <strong>SIRT3-mediated inhibition of FOS through histone H3 deacetylation prevents cardiac fibrosis and inflammation.<\/strong> Signal Transduct Target Ther. 2020 Feb 28;5(1):14.<\/li>\n<li>Zarei M, et al. <strong>Hepatic regulation of VLDL receptor by PPAR<\/strong><strong>\u03b2<\/strong><strong>\/<\/strong><strong>\u03b4<\/strong><strong> and FGF21 modulates non-alcoholic fatty liver disease.<\/strong> Mol Metab. 2018 Feb;8:117-131.<\/li>\n<li>Botteri G et al. <strong>VLDL and apolipoprotein CIII induce ER stress and inflammation and attenuate insulin signalling via Toll-like receptor 2 in mouse skeletal muscle cells.<\/strong> Diabetologia. 2017 Nov;60(11):2262-2273.<\/li>\n<li>Zarei M, et al. <strong>Heme-Regulated eIF2<\/strong><strong>\u03b1<\/strong><strong> Kinase Modulates Hepatic FGF21 and Is Activated by PPAR<\/strong><strong>\u03b2<\/strong><strong>\/<\/strong><strong>\u03b4<\/strong><strong> Deficiency.<\/strong> Diabetes. 2016 Oct;65(10):3185-99.<\/li>\n<\/ul>\n<p>Other group publications: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed?term=Vazquez%20Carrera%20M%5bAuthor%5d\">https<\/a><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed?term=Vazquez%20Carrera%20M%5bAuthor%5d\">:\/\/<\/a><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed?term=Vazquez%20Carrera%20M%5bAuthor%5d\">www.ncbi.nlm.nih.gov\/pubmed?term=Vazquez%20Carrera%20M%5BAuthor%5D<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>With more than 10 years\u2019 experience in the field of pharmacology, inflammation and metabolic diseases, the Laboratory of Pharmacological Targets&#8230;<\/p>\n","protected":false},"author":2,"featured_media":7806,"parent":1468,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-grupsrecerca.php","meta":{"_acf_changed":false,"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-7790","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/pages\/7790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=7790"}],"version-history":[{"count":4,"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/pages\/7790\/revisions"}],"predecessor-version":[{"id":13450,"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/pages\/7790\/revisions\/13450"}],"up":[{"embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/pages\/1468"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/media\/7806"}],"wp:attachment":[{"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=7790"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}